From 081601d72c6c12746bab6418899e3670d503f874 Mon Sep 17 00:00:00 2001 From: borja Date: Wed, 30 Oct 2024 15:03:19 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/InCORNTD 2025___Application.md | 4 ++-- 1 file changed, 2 insertions(+), 2 deletions(-) diff --git a/pages/InCORNTD 2025___Application.md b/pages/InCORNTD 2025___Application.md index 075f700e..3a147686 100644 --- a/pages/InCORNTD 2025___Application.md +++ b/pages/InCORNTD 2025___Application.md @@ -1,6 +1,6 @@ # [[2024/10/30]] - **Título**: Fixed dose albenzadole/ivermectin coformulation, an innovative tool to help countries achieve their NTD control goals in a post-donation era - **Description**: The fixed-dose coformulation of albendazole and ivermectin is the result of 10+ years of innovations carried out by African and European organizations working through public-private partnerships. - This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial and is currently being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA. - The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing better efficacy against more species of helminths. + This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial and is currently under evaluation by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA for registration. + The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control - \ No newline at end of file